Pharmaceuticals

Vyepti Market 2026 driven by increasing migraine prevalence globally

March 27, 2026March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Vyepti Market By The End Of 2030?

The expansion observed historically is linked to a higher incidence of chronic migraine conditions, an increase in the diagnosis of neurological disorders, greater adoption of biologic treatments for migraine, the proliferation of specialized neurology clinics, and enhanced availability of sophisticated migraine therapies.

The anticipated growth in the upcoming period is propelled by the escalating development of next-generation monoclonal antibodies, a surging demand for preventive migraine care, the expansion of personalized neurological treatment approaches, increasing investments in biologic drug pipelines, and a heightened focus on long-duration migraine therapies. Concurrently, major trends expected during this forecast period include the rising adoption of CGRP-targeted migraine therapies, a growing reliance on long-acting preventative migraine treatments, an intensifying emphasis on biologic-based neurological drugs, the broadening of hospital-based infusion therapies, and an enhanced commitment to personalized migraine management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20434&type=smp

What Primary Drivers Are Shaping The Development Of The Vyepti Market?

The rising incidence of migraines is anticipated to boost the vyepti market’s expansion in the future. Migraines are intense headaches frequently occurring with symptoms like sickness, throwing up, and heightened sensitivity to illumination or noise. The widespread occurrence of migraines stems from a mix of genetic, environmental, and personal habits, such as changes in hormones, emotional strain, irregular sleep, and specific food triggers. Vyepti (eptinezumab) addresses migraines by focusing on and blocking the CGRP (calcitonin gene-related peptide) protein, a crucial element in how migraine headaches develop, thereby lessening how often and how severe migraines are. For instance, in August 2025, according to The Migraine Trust, a UK-based charity organization, A&E attendance for migraine in England rose by 22% in 2023/2024 compared to the previous year. Consequently, the growing occurrence of migraines is stimulating the growth of the vyepti market.

Which Segment Classifications Shape The Vyepti Market?

The vyepti market covered in this report is segmented –

1) By Indication: Chronic Migraine, Episodic Migraine, Other Neurological Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End User: Adult, Geriatric

How Are Trends Impacting The Vyepti Market?

A primary development within the Vyepti market involves the worldwide reach of cutting-edge migraine prevention treatments into significant Asian territories, thereby enhancing availability for patient groups with insufficient access. This development underscores the increasing priority on introducing biologic medications to nations where preventive solutions for migraine are still scarce. Illustratively, in November 2025, the Danish pharmaceutical firm H. Lundbeck A/S received approval for its new drug application for Vyepti (eptinezumab) from Japan’s Ministry of Health, Labour and Welfare (MHLW), signaling a major advancement toward its introduction across principal Asian markets. Vyepti (eptinezumab) functions as a humanized monoclonal antibody designed to target calcitonin gene-related peptide (CGRP), an essential molecule implicated in migraine attacks. Administered intravenously, it aims to deliver swift and lasting alleviation of migraine indications.

Which Companies Are Expanding Their Footprint In The Vyepti Market?

Major companies operating in the vyepti market are H. Lundbeck A/S.

Read the full vyepti market report here:

https://www.thebusinessresearchcompany.com/report/vyepti-global-market-report

How Does The Vyepti Market Perform Across Major Global Regions?

North America was the largest region in the vyepti market in 2025. The regions covered in the vyepti market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vyepti Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20434&type=smp

Browse Through More Reports Similar to the Global Vyepti Market 2026, By The Business Research Company

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795